---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-036302"
form_type: "8-K"
ticker: "AIXC"
cik: "0001460702"
company_name: "AIxCrypto Holdings, Inc."
filed_at: "2022-12-22T23:59:59+00:00"
generated_at: "2026-06-20T23:59:46.450009+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Qualigen Therapeutics issues $3.3M 8% convertible debenture and warrant to Alpha Capital

## Summary
- Issued $3.3M principal debenture for $3M purchase price; 8% interest starts Dec 2023, payable quarterly.
- Conversion price $1.32/share; warrant for 2.5M shares at exercise price $1.65, exercisable from June 2023 to June 2028.
- Proceeds to advance QN-302 IND candidate toward clinical trials and for working capital.
- Monthly redemption of $110k+ interest begins June 2023, with optional redemption at 105% of principal.
- Debenture and warrant unregistered, issued under Section 4(a)(2) exemption; registration rights agreement filed.

## SEC filing metadata
- accession: 0001493152-22-036302
- form_type: 8-K
- ticker: AIXC
- cik: 0001460702
- company_name: AIxCrypto Holdings, Inc.
- filed_at: 2022-12-22T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460702/000149315222036302/0001493152-22-036302-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460702/000149315222036302/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-036302
- JSON: https://secwatch.observer/filing/0001493152-22-036302.json
- Plain text: https://secwatch.observer/filing/0001493152-22-036302.txt

## Key facts
- Debt Financings
  AIxCrypto Holdings, Inc. incurred convertible notes of $3,300,000 with Alpha Capital Anstalt at 8% per annum maturing December 22, 2025.
  - Instrument: convertible notes
  - Principal: $3,300,000
  - Counterparty: Alpha Capital Anstalt
  - Rate: 8% per annum
  - Maturity: December 22, 2025
  - Event: incurrence
  source text: Alpha Capital Anstalt (“Alpha”), pursuant to which it agreed to issue to Alpha, an 8% Senior Convertible Debenture (the “Debenture”) in the aggregate principal amount of $3,300,000 for a purchase price of $3,000,000. The Debenture will be convertible, at any time, and from time to time, at Alpha’s option, into shares of common stock of the Company (the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460702/000149315222036302/0001493152-22-036302-index.htm
- Material Agreements
  AIxCrypto Holdings, Inc. entered into Securities Purchase Agreement with Alpha Capital Anstalt valued at $3,300,000 (effective 2022-12-21).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Alpha Capital Anstalt
  - Value: $3,300,000
  - Effective: 2022-12-21
  source text: On December 21, 2022, Qualigen Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (“Agreement”) with Alpha Capital Anstalt (“Alpha”), pursuant to which it agreed to issue to Alpha, an 8% Senior Convertible Debenture (the “Debenture”) in the aggregate principal amount of $3,300,000 for a purchase price of $3,000,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460702/000149315222036302/0001493152-22-036302-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.